CN100432072C - 吡咯取代的吲哚满酮化合物的盐和多晶型物 - Google Patents

吡咯取代的吲哚满酮化合物的盐和多晶型物 Download PDF

Info

Publication number
CN100432072C
CN100432072C CNB2004800287364A CN200480028736A CN100432072C CN 100432072 C CN100432072 C CN 100432072C CN B2004800287364 A CNB2004800287364 A CN B2004800287364A CN 200480028736 A CN200480028736 A CN 200480028736A CN 100432072 C CN100432072 C CN 100432072C
Authority
CN
China
Prior art keywords
pyrrole
fluoro
maleic acid
hydroxyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800287364A
Other languages
English (en)
Chinese (zh)
Other versions
CN1863796A (zh
Inventor
A·布拉斯克
Q·金
Q·陆
M·A·毛拉季斯
D·宋
B·S·冯德维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CN1863796A publication Critical patent/CN1863796A/zh
Application granted granted Critical
Publication of CN100432072C publication Critical patent/CN100432072C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB2004800287364A 2003-10-02 2004-09-20 吡咯取代的吲哚满酮化合物的盐和多晶型物 Expired - Fee Related CN100432072C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50810403P 2003-10-02 2003-10-02
US60/508,104 2003-10-02

Publications (2)

Publication Number Publication Date
CN1863796A CN1863796A (zh) 2006-11-15
CN100432072C true CN100432072C (zh) 2008-11-12

Family

ID=34421700

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800287364A Expired - Fee Related CN100432072C (zh) 2003-10-02 2004-09-20 吡咯取代的吲哚满酮化合物的盐和多晶型物

Country Status (25)

Country Link
US (1) US7247627B2 (https=)
EP (1) EP1670785B1 (https=)
JP (1) JP4933259B2 (https=)
KR (2) KR20080007520A (https=)
CN (1) CN100432072C (https=)
AR (1) AR047762A1 (https=)
AT (1) ATE473223T1 (https=)
AU (1) AU2004277464B2 (https=)
BR (1) BRPI0415022A (https=)
CA (1) CA2540639C (https=)
CY (1) CY1110771T1 (https=)
DE (1) DE602004028028D1 (https=)
DK (1) DK1670785T3 (https=)
ES (1) ES2348623T3 (https=)
IL (1) IL174414A (https=)
MX (1) MXPA06003661A (https=)
NO (1) NO20061246L (https=)
NZ (1) NZ546001A (https=)
PL (1) PL1670785T3 (https=)
PT (1) PT1670785E (https=)
RU (1) RU2319702C2 (https=)
SI (1) SI1670785T1 (https=)
TW (1) TW200524921A (https=)
WO (1) WO2005033098A1 (https=)
ZA (1) ZA200602691B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
KR20070104673A (ko) * 2005-03-23 2007-10-26 화이자 프로덕츠 인코포레이티드 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법
CN101267824A (zh) * 2005-09-20 2008-09-17 辉瑞产品公司 使用酪氨酸激酶抑制剂的治疗剂型和方法
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
CN101631747B (zh) * 2007-04-04 2012-09-19 大塚化学株式会社 钛酸钾及其制造方法、以及摩擦材料和树脂组合物
US8063043B2 (en) * 2008-09-17 2011-11-22 Novartis Ag Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
RU2430361C1 (ru) * 2010-07-05 2011-09-27 Государственное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет им. В.Ф. Войно-Ясенецкого Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития диабетической ретинопатии при сахарном диабете типа 2 у якутов
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9851313B2 (en) * 2015-03-03 2017-12-26 Panalytical B.V. Quantitative X-ray analysis—ratio correction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066463A1 (en) * 2001-02-15 2002-08-29 Pharmacia & Upjohn Company 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1575936A3 (ru) * 1986-04-10 1990-06-30 Е.И.Дюпон Де Немур Энд Ко.(Фирма) Способ получени 3,3-дизамещенных индолин-2-ионов или их солей
US5534522A (en) * 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
GEP20063777B (en) * 2001-08-15 2006-03-27 Upjohn Co Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
YU67702A (sh) 2001-09-28 2004-12-31 Pfizer Products Inc. Postupak za dobijanje alkansulfonil piridina
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
EP1476443A2 (en) * 2002-02-15 2004-11-17 PHARMACIA & UPJOHN COMPANY Process for preparing indolinone derivatives
PY0323128A (es) * 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066463A1 (en) * 2001-02-15 2002-08-29 Pharmacia & Upjohn Company 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
ATE473223T1 (de) 2010-07-15
DK1670785T3 (da) 2010-10-18
AU2004277464A1 (en) 2005-04-14
CY1110771T1 (el) 2015-06-10
JP4933259B2 (ja) 2012-05-16
AR047762A1 (es) 2006-02-22
PT1670785E (pt) 2010-09-16
PL1670785T3 (pl) 2010-12-31
SI1670785T1 (sl) 2010-10-29
WO2005033098A8 (en) 2006-04-20
JP2007507482A (ja) 2007-03-29
RU2006110541A (ru) 2006-08-27
IL174414A0 (en) 2008-02-09
MXPA06003661A (es) 2006-06-05
CA2540639C (en) 2010-08-31
EP1670785B1 (en) 2010-07-07
DE602004028028D1 (de) 2010-08-19
CA2540639A1 (en) 2005-04-14
BRPI0415022A (pt) 2006-11-28
KR20080007520A (ko) 2008-01-21
HK1093068A1 (zh) 2007-02-23
ZA200602691B (en) 2007-06-27
AU2004277464B2 (en) 2010-07-08
US7247627B2 (en) 2007-07-24
IL174414A (en) 2011-12-29
WO2005033098A9 (en) 2006-05-26
NZ546001A (en) 2009-09-25
RU2319702C2 (ru) 2008-03-20
CN1863796A (zh) 2006-11-15
WO2005033098A1 (en) 2005-04-14
KR20060058728A (ko) 2006-05-30
TW200524921A (en) 2005-08-01
NO20061246L (no) 2006-03-29
ES2348623T3 (es) 2010-12-09
US20050118255A1 (en) 2005-06-02
EP1670785A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
JP5894714B1 (ja) 上皮成長因子受容体の活性化変異型のキナゾリン阻害剤
EP1625121A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
US6642232B2 (en) 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
CN100432072C (zh) 吡咯取代的吲哚满酮化合物的盐和多晶型物
CN1729001A (zh) 用于治疗异常细胞生长的4－苯胺基喹唑啉衍生物
RU2369607C1 (ru) Соли и полиморфные модификации ингибитора vegf-r
HK1093068B (en) Salts and polymorphs of a pyrrole-substituted indolinone compound
CN101238118A (zh) Vegf-r抑制剂的盐及多晶型
AU2024327686A1 (en) Pyrazole compounds as cullin ring ubiquitin ligase compounds
HK1082211A (en) 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1093068

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1093068

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081112

Termination date: 20140920

EXPY Termination of patent right or utility model